Skip to content
Making medicines and medical devices safer

What is being reported

The MHRA is transparent in the data it receives via the Yellow Card scheme.

For suspected side effects being reported, the MHRA publishes this information in the form of interactive Drug Analysis Profiles (iDAPs) which can be accessed below. There is an iDAP for each licensed medicines by drug substance. Within an iDAP you can see all suspected side effects, known as suspected adverse drug reactions, that are reported to the MHRA. 

You can access COVID-19 information received via the Yellow Card scheme here.

interactive Drug Analysis Profiles (iDAPs)

iDAPs enable you to interact with the data so you can understand more about the types of reactions that have been reported, and at a high level about who experienced the side effects.

Medicines are listed alphabetically by the name of the active ingredient, not by the brand name. To find the name of the active substance in your medicine, look at the patient information leaflet that was supplied with it. You can find patient information leaflets here.

Each iDAP contains complete data for all spontaneous side effects, known as suspected adverse drug reactions via the Yellow Card scheme from healthcare professionals and members of the public. They also include reports from pharmaceutical companies. Information regarding suspected adverse reactions to vaccines is not currently available via the iDAPs but is available upon request.

iDAPs provided on this website are regularly updated. Please be aware, however, that if you have reported a suspected adverse drug reaction it may not immediately appear on this website. There is a time lag of around one month from receipt of a report to it appearing in the iDAP.

When reviewing the data within an iDAP it is important to do so in the context of the essential guidance at the bottom of the report and before to ensure that you do not misinterpret the data.

Questions & comments

During their development iDAPs have been extensively tested with a variety of stakeholders, nevertheless if you have any questions or comments about how they should be used/ interpreted or if the substance you are interested in is not currently available, please do not hesitate to contact us.